Compass Therapeutics Inc Stock Price, News & Analysis

Compass Therapeutics (Nasdaq: CMPX) announced the first patient dosed in a Phase 1b study of CTX-471 combined with KEYTRUDA® for treating advanced solid tumors, including lung and head & neck cancers.

The study aims to evaluate CTX-471's ability to restore responses after checkpoint inhibitor therapy. Previous monotherapy results showed signs of activity.

CTX-471 is a CD137 agonist that activates key immune cells. Four partial responses were observed in earlier trials as of September 30, 2022.

Compass Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatment, will participate in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York City. The company's presentation is scheduled for December 1, 2022, at 8:50 AM ET. A webcast link will be available on their website, and the corporate presentation will be archived for 90 days. Compass Therapeutics is dedicated to developing antibody-based therapies targeting key biological pathways to enhance anti-tumor responses.

Compass Therapeutics (CMPX) announced financial results for Q3 2022, reporting a net loss of $12 million, or $0.12 per share, compared to $6 million, or $0.10 per share, in Q3 2021. Cash and marketable securities were $120.6 million, down from $144.5 million at the end of 2021. The company raised approximately $80 million through a PIPE financing to extend its cash runway into 2026. Key clinical trials for CTX-009 and CTX-471 are underway, with patient enrollment expected to start in Q4 2022. R&D expenses surged by 210% year-over-year, reflecting increased development activities.

BOSTON, Nov. 08, 2022 - Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in two key investor conferences this November. The Stifel Healthcare Conference in New York City is scheduled for November 15, 2022, from 4:10-4:40 PM ET. The Jefferies Global Healthcare Conference in London will take place on November 16, 2022, from 3:15-3:45 PM GMT. Both presentations will be available via webcast, with a replay accessible for 90 days. Compass Therapeutics focuses on developing antibody-based therapies targeting cancer.

Compass Therapeutics, Inc. (CMPX) announced a private investment in public equity (PIPE) financing, selling 25 million shares at $3.21 each, totaling approximately $80 million. The financing, led by Enavate Sciences and other institutional investors, is expected to close by November 8, 2022. Funds will advance their clinical pipeline, including CTX-009, CTX-471, and CTX-8371, extending the company's cash runway into 2026. The securities have not been registered under the Securities Act but will be subject to a registration rights agreement for resale.

Compass Therapeutics (Nasdaq: CMPX) announced a clinical trial collaboration with Merck to evaluate its monoclonal antibody CTX-471 in combination with KEYTRUDA^® for treating advanced cancers post anti-PD-1 therapy. The Phase 1b trial will enroll patients with various cancer types and assess safety, pharmacokinetics, and clinical activity. Initial results from earlier trials showed partial responses in patients. This collaboration marks a significant advancement in cancer immunotherapy.

Compass Therapeutics (Nasdaq: CMPX) announced its participation in the 24th Annual H.C. Wainwright Global Investment Conference in New York City, scheduled for September 12 – 14, 2022. The company's presentation is set for September 13, 2022, at 2:30 PM EDT. A webcast of the presentation will be available and archived on their Events page for 90 days.

Compass Therapeutics, Inc. (Nasdaq: CMPX) will present at the 2022 Wedbush PacGrow Healthcare Conference, scheduled virtually for August 9-10, 2022. The presentation is set for August 9 at 4:05 pm ET. Interested parties can access the webcast here, and it will be available for replay for 90 days on Compass’s Events page.

Compass Therapeutics focuses on developing antibody-based therapeutics aimed at treating cancer by targeting critical biological pathways.

Compass Therapeutics (CMPX) reported Q2 2022 results with a net loss of $8.5M ($0.08/share), down from $55.8M ($1.07/share) in Q2 2021. Cash and marketable securities totaled $132M, extending their runway into H2 2024. The company is set to initiate a Phase 2/3 trial for CTX-009 in biliary tract cancer (BTC) and a Phase 2 trial for advanced colorectal cancer (CRC) by Q4 2022. Additionally, CTX-471 continues to show efficacy in mesothelioma patients, with four reported partial responses. R&D expenses rose to $5.9M from $2.9M, while G&A expenses increased to $3.1M from $2.2M, reflecting ongoing operational growth.